Treatment for Depressed, Obese Individuals at Risk for Cardiovascular Disease (CVD)

NCT ID: NCT01692574

Last Updated: 2016-08-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine whether individuals who suffer from depression and obesity are able to lose weight and show improvements in mood and cardiovascular disease risk factors following 20 weeks of a combined treatment of cognitive-behavior therapy for depression and behavior modification for weight loss. Participants will be assigned to one of three treatments: 1) cognitive-behavior therapy for the treatment of depression combined with an alternative approach to weight loss, 2) a weight loss intervention combined with a depression support and education , or 3) cognitive-behavioral therapy for depression combined with a weight loss intervention.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Major Depressive Disorder Dysthymic Disorder Cardiovascular Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Combined

Group cognitive-behavior therapy for depression combined with behavior modification for weight loss

Group Type EXPERIMENTAL

Behavior Modification for Weight Loss

Intervention Type BEHAVIORAL

Cognitive-Behavior Therapy for Depression

Intervention Type BEHAVIORAL

GCBT-ND

Group cognitive-behavior therapy for depression combined with an alternative approach to weight loss

Group Type ACTIVE_COMPARATOR

Alternative Approach to Weight Loss

Intervention Type BEHAVIORAL

Cognitive-Behavior Therapy for Depression

Intervention Type BEHAVIORAL

DSE

Behavior modification for weight loss combined with depression support and education.

Group Type ACTIVE_COMPARATOR

Behavior Modification for Weight Loss

Intervention Type BEHAVIORAL

Depression Support and Education

Intervention Type BEHAVIORAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Behavior Modification for Weight Loss

Intervention Type BEHAVIORAL

Alternative Approach to Weight Loss

Intervention Type BEHAVIORAL

Cognitive-Behavior Therapy for Depression

Intervention Type BEHAVIORAL

Depression Support and Education

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female and male participants, with a BMI of 27 kg/m2 to 45 kg/m2
* Age 18 - 70 years old
* Presence of current major depressive disorder or dysthymic disorder
* At least 2 CVD risk factors, as characterized by the metabolic syndrome, including:

* Elevated waist circumference (males 40 inches or 102 cm; females 35 inches of 88 cm)
* Fasting blood glucose 100 mg/dL
* Blood pressure 130/85 mm Hg
* Triglycerides 150 mg/dL
* Reduced HDL cholesterol (males 40 mg/dL; females 50 mg/dL)
* OR medications for these conditions
* Able to comply will all study procedures and schedule
* Able to speak and read English

Exclusion Criteria

* Cardiovascular event (e.g., myocardial infarction, stroke) within the past 12 months
* Use of tricyclic anti-depressants, monoamine oxidase inhibitors or paroxetine, mood stabilizers, or antipsychotic medications. (Note: participants who take SSRI/SNRI may be acceptable, provided they have been on a stable dose of these medications 3 months.)
* Use of weight-loss medications or any medications known to significantly affect weight (e.g., oral steroids) in past 3 months
* Weight loss of 5% or more in past 6 months
* Enrollment in weight reduction program in prior 3 months
* Treatment in individual psychotherapy for any psychiatric disorder in prior 3 months (Note: participants in couples or family counseling will be allowed.)
* Severe depression or severe impairment of functioning as judged by the assessor or PI
* Presence of active suicidal ideation
* Diabetes
* Alcohol/drug abuse/dependence
* Renal/hepatic disease
* Change in thyroid medications in last 3 months
* Pregnant/lactating, within 6-months post-partum
* Current diagnoses, or history within the last 5 years, of anorexia or bulimia
* Psychotic symptoms or hospitalization for a psychiatric disorder in previous 12 months
* Mood disorder NOS, substance-induced mood disorders, mood disorders due to a general medical condition
* History of bipolar disorder
* History of head trauma
* Any changes in smoking behavior in prior 3 months (or plans to change in the next 3 months)
* Plans for bariatric surgery
* Any other uncontrolled major medical problems
* Women who are pregnant
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role collaborator

University of Pennsylvania

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lucy F Hemsley-Faulconbridge, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Pennsylvania Center for Weight and Eating Disorders

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Pennsylvania: Center for Weight and Eating Disorders

Philadelphia, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Faulconbridge LF, Driscoll CFB, Hopkins CM, Bailer Benforado B, Bishop-Gilyard C, Carvajal R, Berkowitz RI, DeRubeis R, Wadden TA. Combined Treatment for Obesity and Depression: A Pilot Study. Obesity (Silver Spring). 2018 Jul;26(7):1144-1152. doi: 10.1002/oby.22209.

Reference Type DERIVED
PMID: 29932516 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

813829

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Beating the Blues for Your Heart
NCT01605552 COMPLETED PHASE2